MX2017005524A - Metodos y composiciones para el virus del dengue recombinante para el desarrollo de vacunas y de diagnostico. - Google Patents

Metodos y composiciones para el virus del dengue recombinante para el desarrollo de vacunas y de diagnostico.

Info

Publication number
MX2017005524A
MX2017005524A MX2017005524A MX2017005524A MX2017005524A MX 2017005524 A MX2017005524 A MX 2017005524A MX 2017005524 A MX2017005524 A MX 2017005524A MX 2017005524 A MX2017005524 A MX 2017005524A MX 2017005524 A MX2017005524 A MX 2017005524A
Authority
MX
Mexico
Prior art keywords
methods
dengue virus
compositions
vaccines
virus
Prior art date
Application number
MX2017005524A
Other languages
English (en)
Inventor
Baric Ralph
DESILVA Aravinda
Yount Boyd
Widman Douglas
Gallichotte Emily
ROYAL Scott
Swanstrom Jesica
Original Assignee
Univ North Carolina Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina Chapel Hill filed Critical Univ North Carolina Chapel Hill
Publication of MX2017005524A publication Critical patent/MX2017005524A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

La presente invención proporciona composiciones y métodos de uso que comprenden una glicoproteína E del virus del dengue quimérico que comprende un cadena principal de glicoproteína E del virus del dengue, que comprende sustituciones de aminoácidos que introducen un epítopo que es reconocido por un anticuerpo de un serotipo del virus del dengue que es diferente del serotipo del virus del dengue de la cadena principal de la glicoproteína E del virus del dengue.
MX2017005524A 2014-11-02 2015-11-02 Metodos y composiciones para el virus del dengue recombinante para el desarrollo de vacunas y de diagnostico. MX2017005524A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462074053P 2014-11-02 2014-11-02
PCT/US2015/058610 WO2016070178A1 (en) 2014-11-02 2015-11-02 Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development

Publications (1)

Publication Number Publication Date
MX2017005524A true MX2017005524A (es) 2018-01-26

Family

ID=55858450

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005524A MX2017005524A (es) 2014-11-02 2015-11-02 Metodos y composiciones para el virus del dengue recombinante para el desarrollo de vacunas y de diagnostico.

Country Status (12)

Country Link
US (2) US10398768B2 (es)
EP (1) EP3212672A4 (es)
JP (1) JP6671364B2 (es)
KR (1) KR20170075775A (es)
CN (1) CN107207619A (es)
AU (1) AU2015338859A1 (es)
BR (1) BR112017008952A2 (es)
CA (1) CA2966198A1 (es)
MX (1) MX2017005524A (es)
MY (1) MY179251A (es)
SG (1) SG11201703366RA (es)
WO (1) WO2016070178A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018026845A1 (en) * 2016-08-01 2018-02-08 Inbios International, Inc. Immunoassay methods and compositions for detecting infection involving use of test antigens as cross-reactive control antigens
CN106632620B (zh) * 2016-11-29 2019-08-23 菲鹏生物股份有限公司 登革病毒重组抗原及其制备方法和应用
US11370830B2 (en) 2017-04-07 2022-06-28 The Rockefeller University Neutralizing antibodies that bind to the zika virus domain III envelope region
CN110568190A (zh) * 2019-08-30 2019-12-13 深圳国际旅行卫生保健中心 登革热病毒抗原、检测试剂、检测试纸、检测试剂盒及其使用方法
WO2021102363A1 (en) * 2019-11-20 2021-05-27 The University Of North Carolina At Chapel Hill Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
US20250188130A1 (en) * 2022-03-17 2025-06-12 The University Of North Carolina At Chapel Hill Compositions comprising modified flavivirus e glycoproteins and methods of making and using the same
CN116716322B (zh) * 2023-05-12 2024-05-31 中山大学 一种denv-3全长感染性克隆及其构建方法与应用
WO2024238948A2 (en) * 2023-05-17 2024-11-21 University Of Iowa Research Foundation Dengue virus serotype-specific modulation of t cell responses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US7476390B2 (en) * 2002-02-26 2009-01-13 Maxygen, Inc. Flavivirus antigens
EP1773403B1 (en) 2004-07-09 2018-04-25 The University of North Carolina At Chapel Hill Alphavirus-based adjuvants
PL2589602T3 (pl) * 2006-08-15 2016-11-30 Rozwinięcie komponentów szczepionki przeciwko wirusowi dengi
US9821050B2 (en) * 2012-04-02 2017-11-21 The University Of North Carolina At Chapel Hill Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions
ES2745431T3 (es) * 2013-06-26 2020-03-02 Univ North Carolina Chapel Hill Composiciones para vacunas contra el virus del dengue y su uso

Also Published As

Publication number Publication date
US10398768B2 (en) 2019-09-03
SG11201703366RA (en) 2017-05-30
JP2018500878A (ja) 2018-01-18
KR20170075775A (ko) 2017-07-03
BR112017008952A2 (en) 2018-01-16
MY179251A (en) 2020-11-02
EP3212672A4 (en) 2018-04-25
WO2016070178A1 (en) 2016-05-06
US20200230224A1 (en) 2020-07-23
US20170333548A1 (en) 2017-11-23
CA2966198A1 (en) 2016-05-06
EP3212672A1 (en) 2017-09-06
AU2015338859A1 (en) 2017-06-01
JP6671364B2 (ja) 2020-03-25
CN107207619A (zh) 2017-09-26

Similar Documents

Publication Publication Date Title
MX2017005524A (es) Metodos y composiciones para el virus del dengue recombinante para el desarrollo de vacunas y de diagnostico.
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
CY1123358T1 (el) Υδατικο φαρμακευτικο σκευασμα που περιεχει αντισωμα αντι-pd-1 αβελουμαμπη
MX376715B (es) Vacuna contra el virus de la diarrea epidemica porcina.
EA201490659A1 (ru) Вакцины против вируса гриппа и их применения
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
CY1121560T1 (el) Ανοσογονικη συνθεση
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
EA201692541A1 (ru) Вакцины против вируса гриппа и их применения
DK3408295T3 (da) Farmaceutisk sammensætning, som omfatter bispecifikke antistofkonstruktioner
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
MX2019007252A (es) Metodos y composiciones para vacunas del virus del dengue.
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
MX373792B (es) Coronavirus.
EA201591465A1 (ru) Специфичные участки для модификации антител для получения иммуноконъюгатов
CR20150170A (es) Vacunas de inmersión subunidad para peces
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
MX2018002164A (es) Anticerpo anti-epha4.
MX379510B (es) Coronavirus bovino atenuado y vacunas relacionadas.
IN2014MU01248A (es)
BR112016019389A8 (pt) Vacina, e, peptídeo
MX2019007924A (es) Vacunas contra la influenza.